T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals
L Hunt, EM Hensor, J Nam, AN Burska… - Annals of the …, 2016 - ard.bmj.com
Objectives Anticitrullinated protein antibody (ACPA)+ individuals with non-specific musculoskeletal
symptoms are at risk of inflammatory arthritis (IA). This study aims to demonstrate the …
symptoms are at risk of inflammatory arthritis (IA). This study aims to demonstrate the …
Predicting inflammatory arthritis in at-risk persons: development of scores for risk stratification
L Duquenne, EM Hensor, M Wilson… - Annals of Internal …, 2023 - acpjournals.org
Background: Inflammatory arthritis (IA) is an immune-related condition defined by the presence
of clinical synovitis. Its most common form is rheumatoid arthritis. Objective: To develop …
of clinical synovitis. Its most common form is rheumatoid arthritis. Objective: To develop …
Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse
…, SL Field, AK Brown, EM Hensor… - Annals of the …, 2008 - ard.bmj.com
Objectives: An abnormal CD4+ T cell subset related to inflammation exposure (inflammation-related
cells, IRC) has been identified in rheumatoid arthritis (RA). Patients with …
cells, IRC) has been identified in rheumatoid arthritis (RA). Patients with …
SAT0107 Sequential ultrasound shows a late increase in inflammatory burden in anti-ccp positive patients with non-specific musculoskeletal symptoms just before …
P Pentony, K Mankia, EM Hensor, JL Nam, L Hunt… - 2018 - ard.bmj.com
Background US abnormalities occur in patients with new rheumatoid arthritis (RA) and can
also predict the development of clinical synovitis in anti-CCP positive patients with …
also predict the development of clinical synovitis in anti-CCP positive patients with …
OP0042 In acpa positive at-risk individuals, which mri and us findings best predict development of clinical synovitis?
L Hunt, J Nam, EM Hensor, K Mankia, E Rowbotham… - 2018 - ard.bmj.com
Background ACPA +individuals with non-specific MSK symptoms are at risk of inflammatory
arthritis (IA) and may benefit from early intervention. Clinical, serological and US markers …
arthritis (IA) and may benefit from early intervention. Clinical, serological and US markers …
A9. 05 Distinct subsets of interferon-stimulated genes are associated with incomplete and established systemic lupus erythematosus
EWRR Abstracts Page 1 Associations of elevated sBAFF with a SNP in the 5regulatory region
of the BAFF genewere reported in patients with autoimmune diseases, together with TTTT …
of the BAFF genewere reported in patients with autoimmune diseases, together with TTTT …
Comment on: tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
…, C Iñiguez Ubiaga, EM Hensor… - … Advances in Practice, 2018 - academic.oup.com
SIR, We read with interest the report by Yahya et al.[1] on tumour necrosis factor inhibitor (TNFi)
survival and predictors of response in axial spondyloarthritis (axSpA) patients treated in …
survival and predictors of response in axial spondyloarthritis (axSpA) patients treated in …
A9. 06 Analysis of cell-specific interferon response in systemic lupus erythematosus using a novel flow cytometric assay
Background and objectives Type I interferons (IFN-I) have diverse effects on immune cell
populations in SLE, Measuring IFN-I using whole blood interferon-stimulated gene (ISG) …
populations in SLE, Measuring IFN-I using whole blood interferon-stimulated gene (ISG) …
O14 Rituximab objective outcome measures trial in SLE (ROOTS): outcomes of randomised and rescue rituximab therapy in a double-blind randomised placebo …
Objective (i) Assess a novel musculoskeletal SLE trial design with objective eligibility and
endpoints and a low-glucocorticoid standard of care; (ii) further validate Lupus Arthritis and …
endpoints and a low-glucocorticoid standard of care; (ii) further validate Lupus Arthritis and …
[HTML][HTML] Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational …
…, J Andrews, J Greenwood, P Baxter, EM Hensor… - 2021 - europepmc.org
Background The VEDERA (Very Early vs. Delayed Etanercept in Rheumatoid Arthritis)
randomised controlled trial compared the effect of conventional synthetic disease-modifying anti-…
randomised controlled trial compared the effect of conventional synthetic disease-modifying anti-…